In line with our findings, we observed that AML cells with high ME1 expression are more resistant to venetoclax and obatoclax, and more sensitive to mTOR inhibitors, which was also reported by Zeng et al., 2022 when analyzing primitive and mature blasts, respectively [29]. The gene discussed is MTOR; the disease is acute myeloid leukemia.